Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City

Abstract

A 3-dose TDV regimen had a favorable safety profile in children and adults and elicited neutralizing antibody responses against all 4 serotypes. These findings support the continued development of this vaccine.

Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans

“…14 More recently, a study in children and adults in Mexico City found that the immune responses to the four dengue serotypes elicited by a two-dose TDV vaccination regimen in subjects primed with YF were comparable with those elicited by a three-dose TDV vaccination regimen in flavivirus-naïve subjects. 15 Another study, also conducted in Mexico, found that previous Japanese encephalitis vaccination could also provide a priming effect, where dengue seropositivity rates and GMTs after one dose of TDV in subjects primed with Japanese encephalitis vaccine were higher than in naïve subjects who received two doses of TDV (Gal an JF, and others, unreported data). Pre-existing flavivirus immunity, therefore, consistently increases antibody responses to the tetravalent dengue vaccine.…”

Development of Sanofi Pasteur tetravalent dengue vaccine

“…Phase I and II clinical trials with a 3-dose vaccination regimen over 12 months demonstrate that this candidate vaccine elicits neutralizing antibodies against all four serotypes in both children and adults with a good safety profile 13,16,17 .…”

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

“…[6][7][8] The investigational, YF-17D-based, recombinant, live, attenuated tetravalent dengue vaccine being developed by Sanofi Pasteur (CYD-TDV), 9,10 is one of several dengue vaccines in development 11,12 and has demonstrated satisfactory safety and immunogenicity, and protective efficacy for 3 of the 4 serotypes. [13][14][15][16][17][18] We have previously shown that CYD-TDV vaccination in adults induces significant CD8 + T-cell responses against the YF-17D backbone of the CYD vaccine viruses and T helper 1 (Th1) responses to each dengue serotype without inducing changes in serum pro-inflammatory cytokines. 19 Here we expand on these investigations and report on cellular responses up to one year after CYD-TDV vaccination of a cohort of adolescents and adults recruited in a dengue low endemic area.…”